News: NOX Noxopharm Says Veyonda Survival Advantage In LuPSMA Therapy Confirmed

  1. 193,698 Posts.
    lightbulb Created with Sketch. 2825

    Aug 5 (Reuters) - Noxopharm Ltd (NOX) :

    • VEYONDA SURVIVAL ADVANTAGE IN LUPSMA THERAPY CONFIRMED
    • ANIMAL STUDY SHOWS ADDING VEYONDA TO 177LUTETIUM-PSMA-617 RESULTS IN REGRESSION OF PROSTATE CANCER
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.8¢
Change
-0.007(6.67%)
Mkt cap ! $28.63M
Open High Low Value Volume
9.7¢ 10.0¢ 9.7¢ $8.946K 91.04K

Buyers (Bids)

No. Vol. Price($)
2 73788 9.7¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 108477 3
View Market Depth
Last trade - 12.32pm 11/09/2025 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.